These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

966 related items for PubMed ID: 27959701

  • 1. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
    Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP.
    N Engl J Med; 2017 Feb 02; 376(5):429-439. PubMed ID: 27959701
    [Abstract] [Full Text] [Related]

  • 2. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
    Kutlar A, Kanter J, Liles DK, Alvarez OA, Cançado RD, Friedrisch JR, Knight-Madden JM, Bruederle A, Shi M, Zhu Z, Ataga KI.
    Am J Hematol; 2019 Jan 02; 94(1):55-61. PubMed ID: 30295335
    [Abstract] [Full Text] [Related]

  • 3. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP, Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    N Engl J Med; 2018 Jul 19; 379(3):226-235. PubMed ID: 30021096
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.
    Delgado J, Voltz C, Stain M, Lapveteläinen T, Urach S, Lähteenvuo J, Penttilä K, Gisselbrecht C, Enzmann H, Pignatti F.
    Hemasphere; 2021 Jul 19; 5(7):e604. PubMed ID: 34235401
    [Abstract] [Full Text] [Related]

  • 7. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
    Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC, DOVE Investigators.
    N Engl J Med; 2016 Feb 18; 374(7):625-35. PubMed ID: 26644172
    [Abstract] [Full Text] [Related]

  • 8. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov 18; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 9. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Biemond BJ, Tombak A, Kilinc Y, Al-Khabori M, Abboud M, Nafea M, Inati A, Wali Y, Kristensen J, Kowalski J, Donnelly E, Ohd J, TVOC01 Investigators Group.
    Lancet Haematol; 2021 May 18; 8(5):e334-e343. PubMed ID: 33894169
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.
    Afana MS, Abu-Tineh M, Alshurafa A, Yasin AK, Ahmed K, Abdulgayoom M, Yassin MA.
    Hematology; 2023 Dec 18; 28(1):2229115. PubMed ID: 37519115
    [Abstract] [Full Text] [Related]

  • 13. Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.
    Sy SKB, Tanaka C, Grosch K.
    Clin Pharmacokinet; 2023 Feb 18; 62(2):249-266. PubMed ID: 36529836
    [Abstract] [Full Text] [Related]

  • 14. Crizanlizumab: First Approval.
    Blair HA.
    Drugs; 2020 Jan 18; 80(1):79-84. PubMed ID: 31933169
    [Abstract] [Full Text] [Related]

  • 15. Magnesium for treating sickle cell disease.
    Than NN, Soe HHK, Palaniappan SK, Abas AB, De Franceschi L.
    Cochrane Database Syst Rev; 2017 Apr 14; 4(4):CD011358. PubMed ID: 28409830
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A critical evaluation of crizanlizumab for the treatment of sickle cell disease.
    Karki NR, Saunders K, Kutlar A.
    Expert Rev Hematol; 2022 Jan 14; 15(1):5-13. PubMed ID: 34942078
    [Abstract] [Full Text] [Related]

  • 20. Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.
    Stevens DL, Hix M, Gildon BL.
    J Pharm Technol; 2021 Aug 14; 37(4):209-215. PubMed ID: 34752581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.